← Human Trials & Peer-Reviewed Studies
Subcutaneously administered Repronex in oligoovulatory female patients undergoing ovulation induction is as effective and well tolerated as intramuscular human menopausal gonadotropin treatment
Plain-language guide to PMID 11438320 (2001): open-label randomized controlled trial study of HMG (Human Menopausal Gonadotropin).
Key Facts
- PMID
- 11438320
- Journal
- Fertility and sterility
- Year
- 2001
- Study type
- Randomized Controlled Trial
- Authors
- Nichols J et al. (5 authors)
- DOI
- 10.1016/s0015-0282(01)01856-8
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of HMG (Human Menopausal Gonadotropin), published as a randomized controlled trial.
Who Took Part
PubMed indexes the participants as adults, women only.
Premenopausal anovulatory and oligoovulatory females (n = 115) undergoing ovulation induction.
Down-regulation with leuprolide acetate followed by up to 12 days of treatment with gonadotropins and hCG administration and luteal phase progesterone support.
How the Study Was Run
In design terms this was a randomized, open-label, multicenter and parallel-group study.
Because people in this HMG (Human Menopausal Gonadotropin) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Everyone knew when HMG (Human Menopausal Gonadotropin) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.
More than one site took part, so the participants came from several places.
Groups ran in parallel: each of the participants stayed in one arm throughout.
The timeline in the abstract includes 12 days.
Randomized, open-label, multicenter, parallel group study.
Ten academic and private fertility clinics with expertise in ovualtion induction.
What Was Measured
Topics PubMed links to this paper include Fertility Agents, Female, Menotropins, Organic Chemicals, Ovarian Follicle, Ovulation Induction and Self Administration.
What This Means in Plain Language
The paper is a randomized, open-label and multicenter study of HMG (Human Menopausal Gonadotropin) over 12 days.
Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2001 (Fertility and sterility), a journal based in United States.
More context: the HMG (Human Menopausal Gonadotropin) compound page, all human trials.
Our Notes on the Compound
HMG (Human Menopausal Gonadotropin): Menotropins: a glycoprotein preparation that supplies follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.